13 July 2017

The Company Announcements Office ASX Limited

Notice under section 708A(5)(e) of the Corporations Act

On 11 and 12 July 2017, Neuren Pharmaceuticals Limited (the Company) issued 11,935,485 fully paid ordinary shares at an issue price of 6.2 cents per share, as set out in the Appendix 3B lodged on 13 July 2017.

The Company gives this Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).

  1. The shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.

  2. As at the date of this Notice, the Company has complied with:

    1. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

    2. section 674 of the Corporations Act.

    3. As at the date of this Notice, there is no excluded information for the purposes of section 708A(7) and section 708A(8) of the Corporations Act.

      4. Yours sincerely

      Jon Pilcher

      CFO & Company Secretary Neuren Pharmaceuticals

      Neuren Pharmaceuticals Limited ARBN 111 496 130

    Neuren Pharmaceuticals Limited published this content on 13 July 2017 and is solely responsible for the information contained herein.
    Distributed by Public, unedited and unaltered, on 13 July 2017 07:19:07 UTC.

    Original documenthttp://www.neurenpharma.com/irm/PDF/1683_0/Noticeundersection708A5eoftheCorporationsAct

    Public permalinkhttp://www.publicnow.com/view/DF6E08BEFE7D0965C745201BEB2984C64068BF00